Research
Stopping Ozempic may be bad for your health
The Brief
- In people with type 2 diabetes and no established cardiovascular disease, starting GLP-1 treatment and then stopping is associated with twice the combined risk of heart attack, stroke or death compared with staying on treatment.
- The reported finding is an association and comes from the Medical Xpress summary of the study; the source does not give further detail on design or sample size.
Why it matters
For people with type 2 diabetes who have started a GLP-1 drug such as Ozempic, stopping it may carry a higher risk of heart attack, stroke or death than continuing, which is relevant to how clinicians and patients weigh discontinuation.
Who’s affected
- people with type 2 diabetes taking GLP-1 receptor agonists
- clinicians who prescribe GLP-1 treatments
- #type 2 diabetes
- #glp-1
- #cardiovascular risk
- #ozempic
- #medication discontinuation
In people with type 2 diabetes (T2D) and no established cardiovascular disease (CVD), starting glucagon-like peptide-1 receptor agonist (GLP-1) treatment and then stopping is associated with twice the combined risk of heart attack, stroke or death compared with staying on…